Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept

NCT03468296 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

22

Enrollment

OTHER

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: Intravitreal Aflibercept Injection 2mg

Sponsor

Tennessee Retina

Collaborators

[object Object]